The U.S. Biomedical Advanced Research and Development Authority (BARDA) has awarded a $168 million NextGen project contract to ModeX Therapeutics to develop antiviral therapies.
Under the contract, ModeX will utilize its MSTAR technology platform to develop multispecific antibodies that can integrate four to six independent antibody binding sites into a single molecule.
As part of the U.S. government’s Strategic Preparedness and Response arm, BARDA launched the NextGen program to develop vaccines and treatments for emerging infections, including Covid-19, influenza and more. To achieve this goal, BARDA plans to leverage its public-private partnerships and plans to invest more than $5 billion in Project NextGen.
ModeX to receive $59 million in upfront payment to fund Phase I trial, including development, manufacturing and execution of multispecific antibody with broad ability to neutralize known variants of SARS-CoV-2 strains .
The U.S.-based company is also eligible to receive up to $109 million in milestone payments to develop multispecific antibody therapies against other viral pathogens such as influenza. ModeX will also work to develop gene-based multispecific antibody delivery methods using mRNA or DNA vectors.
BARDA is also working with Regeneron Pharmaceuticals to develop a Covid-19 monoclonal antibody vaccine candidate. U.S. government agencies have also contracted with ICON to conduct clinical trials of Project NextGen vaccine candidates.
Access the most comprehensive company profiles on the market, powered by GlobalData. Save time on research. Gain a competitive advantage.
Company Profile – Free Samples
Thank you!
Your download email will arrive soon
We are confident in the unique quality of our company profile.However, we want you to make the decision that’s best for your business, so we offer a free sample that you can download by submitting the form below
By Global Data
In March, ModeX signed an exclusive global license and collaboration agreement with Merck & Co. (MSD) to develop a vaccine candidate for Epstein-Barr virus (EBV), the leading cause of infectious mononucleosis.